Pub Date : 2025-12-10DOI: 10.1038/s43018-025-01082-2
Michelle Monje, Frank Winkler
Over the past decade, multiple lines of inquiry have converged on the appreciation that the nervous system plays crucial roles in cancer pathophysiology. Key conceptual advances will mark 2025 as a milestone year in which the ‘emerging’ cancer neuroscience field developed into an established field. Here, we discuss the latest developments.
{"title":"Key developments in the cancer neuroscience field","authors":"Michelle Monje, Frank Winkler","doi":"10.1038/s43018-025-01082-2","DOIUrl":"10.1038/s43018-025-01082-2","url":null,"abstract":"Over the past decade, multiple lines of inquiry have converged on the appreciation that the nervous system plays crucial roles in cancer pathophysiology. Key conceptual advances will mark 2025 as a milestone year in which the ‘emerging’ cancer neuroscience field developed into an established field. Here, we discuss the latest developments.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 12","pages":"1928-1929"},"PeriodicalIF":28.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1038/s43018-025-01055-5
Bertrand Routy, Edmond Rafie, Arielle Elkrief
Antibiotic-related dysbiosis has emerged as a major, yet potentially modifiable, barrier to immune-checkpoint inhibitor (ICI) efficacy in patients with cancer. Although antibiotic stewardship remains the primary recommendation, the advent of point-of-care microbiome profiling tools and targeted, preventative or restorative interventions may offer strategies to counter antibiotic-related dysbiosis and improve outcomes.
{"title":"Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence","authors":"Bertrand Routy, Edmond Rafie, Arielle Elkrief","doi":"10.1038/s43018-025-01055-5","DOIUrl":"10.1038/s43018-025-01055-5","url":null,"abstract":"Antibiotic-related dysbiosis has emerged as a major, yet potentially modifiable, barrier to immune-checkpoint inhibitor (ICI) efficacy in patients with cancer. Although antibiotic stewardship remains the primary recommendation, the advent of point-of-care microbiome profiling tools and targeted, preventative or restorative interventions may offer strategies to counter antibiotic-related dysbiosis and improve outcomes.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 12","pages":"1909-1912"},"PeriodicalIF":28.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1038/s43018-025-01077-z
Sandra Misale
The initial discovery of an inhibitor of KRAS G12C revolutionized the KRAS field. Since then, more-potent G12C-specific inhibitors, newer allele-specific inhibitors and combinations based on KRAS targeting have advanced through clinical trials, which has led to approval by the US Food and Drug Administration of the first KRAS–EGFR inhibition combinations.
{"title":"The evolving landscape of RAS-targeted therapies","authors":"Sandra Misale","doi":"10.1038/s43018-025-01077-z","DOIUrl":"10.1038/s43018-025-01077-z","url":null,"abstract":"The initial discovery of an inhibitor of KRAS G12C revolutionized the KRAS field. Since then, more-potent G12C-specific inhibitors, newer allele-specific inhibitors and combinations based on KRAS targeting have advanced through clinical trials, which has led to approval by the US Food and Drug Administration of the first KRAS–EGFR inhibition combinations.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 12","pages":"1913-1915"},"PeriodicalIF":28.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1038/s43018-025-01086-y
Hana Aliee, Leire Bejarano-Bosque, Roger Castells-Graells, Deborah Caswell, Mirco Julian Friedrich, Carino Gurjao, Li Ren Kong, Shuang Liu, Simone Minnie, Reineke A. Schoot, Zefang Tang
Twelve early-career researchers who started their independent research groups in 2025 reflect on their experiences from this first year of the journey, describe the opportunities they have had and the challenges they have faced, and share their hopes and plans for the future.
{"title":"The 2025 generation","authors":"Hana Aliee, Leire Bejarano-Bosque, Roger Castells-Graells, Deborah Caswell, Mirco Julian Friedrich, Carino Gurjao, Li Ren Kong, Shuang Liu, Simone Minnie, Reineke A. Schoot, Zefang Tang","doi":"10.1038/s43018-025-01086-y","DOIUrl":"10.1038/s43018-025-01086-y","url":null,"abstract":"Twelve early-career researchers who started their independent research groups in 2025 reflect on their experiences from this first year of the journey, describe the opportunities they have had and the challenges they have faced, and share their hopes and plans for the future.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 12","pages":"1930-1934"},"PeriodicalIF":28.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1038/s43018-025-01080-4
Melanie Senior
Bispecific antibodies and ADCs battle for the limelight, CAR-T therapy sees late surge and China’s growth continues.
双特异性抗体和adc争夺风头，CAR-T疗法姗姗来迟，中国的增长仍在继续。
{"title":"Cancer drug approvals and setbacks in 2025","authors":"Melanie Senior","doi":"10.1038/s43018-025-01080-4","DOIUrl":"10.1038/s43018-025-01080-4","url":null,"abstract":"Bispecific antibodies and ADCs battle for the limelight, CAR-T therapy sees late surge and China’s growth continues.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 12","pages":"1902-1904"},"PeriodicalIF":28.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1038/s43018-025-01076-0
W. Kimryn Rathmell, Lalita A. Shevde
Fostering a nimble, innovative and resilient biomedical workforce is crucial. Here, we consider how to accelerate the readiness of early career investigators to lead, inverting the traditional pyramid view of academia to place them at the top, with expansive possibilities for advancement.
{"title":"Flipping the narrative on launching a rewarding career in academic medicine","authors":"W. Kimryn Rathmell, Lalita A. Shevde","doi":"10.1038/s43018-025-01076-0","DOIUrl":"10.1038/s43018-025-01076-0","url":null,"abstract":"Fostering a nimble, innovative and resilient biomedical workforce is crucial. Here, we consider how to accelerate the readiness of early career investigators to lead, inverting the traditional pyramid view of academia to place them at the top, with expansive possibilities for advancement.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 12","pages":"1918-1921"},"PeriodicalIF":28.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1038/s43018-025-01083-1
Wenners Ballard, Muskan Agarwal, Stephen V. Liu
Targeted therapies continue to transform the landscape of non-small-cell lung cancer (NSCLC). In 2025, the US Food and Drug Administration approved two targeted therapies, an antibody–drug conjugate and a tyrosine kinase inhibitor, for specific molecular subtypes of NSCLC. In this Clinical Outlook, we discuss their impact on the field.
{"title":"Expanding targeted therapy for lung cancer","authors":"Wenners Ballard, Muskan Agarwal, Stephen V. Liu","doi":"10.1038/s43018-025-01083-1","DOIUrl":"10.1038/s43018-025-01083-1","url":null,"abstract":"Targeted therapies continue to transform the landscape of non-small-cell lung cancer (NSCLC). In 2025, the US Food and Drug Administration approved two targeted therapies, an antibody–drug conjugate and a tyrosine kinase inhibitor, for specific molecular subtypes of NSCLC. In this Clinical Outlook, we discuss their impact on the field.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 12","pages":"1916-1917"},"PeriodicalIF":28.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1038/s43018-025-01091-1
As we do every December, we revisit the highs and lows of the past year in a dedicated Focus issue of commissioned comment, news and highlights from the primary research literature.
{"title":"A look back at 2025","authors":"","doi":"10.1038/s43018-025-01091-1","DOIUrl":"10.1038/s43018-025-01091-1","url":null,"abstract":"As we do every December, we revisit the highs and lows of the past year in a dedicated Focus issue of commissioned comment, news and highlights from the primary research literature.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 12","pages":"1901-1901"},"PeriodicalIF":28.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s43018-025-01091-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1038/s43018-025-01062-6
René Bernards, Anton Berns, Johanna A. Joyce, Michael Baumann
Cancer is causing a global health crisis, straining even wealthy nations with rising cases, costs and workforce limits. Europe lags in translating basic research discoveries into clinical applications. We must invest in prevention, fundamental research, clinical trials, biotech support, workforce and patient involvement to stay competitive.
{"title":"European cancer research requires renewed urgency","authors":"René Bernards, Anton Berns, Johanna A. Joyce, Michael Baumann","doi":"10.1038/s43018-025-01062-6","DOIUrl":"10.1038/s43018-025-01062-6","url":null,"abstract":"Cancer is causing a global health crisis, straining even wealthy nations with rising cases, costs and workforce limits. Europe lags in translating basic research discoveries into clinical applications. We must invest in prevention, fundamental research, clinical trials, biotech support, workforce and patient involvement to stay competitive.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 12","pages":"1922-1924"},"PeriodicalIF":28.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：